Pharmaceutical intermediates
Zavegepant Intermediates
7 pharmaceutical intermediates for Zavegepant. Indication: Migraine.
About Zavegepant
- Originator
- Pfizer Inc
- Indication
- Migraine
- Approved Date
- 03/09/2023
- NCE Patent
- 03/09/2028
- DS/DP
- 10/07/2031
Available intermediates
7 intermediates currently listed for Zavegepant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| (R)-METHYL 2-(((BENZYLOXY)CARBONYL)AMINO)-3-(7-METHYL-1H-INDAZOL-5-YL)PROPANOATE | 855778-40-4 | / | / |
| 3-(piperidin-4-yl)quinolin-2(1h)-one hydrochloride | 855778-84-6 | / | / |
| 3-(piperidin-4-yl)quinolin-2(1h)-one | 205058-78-2 | / | / |
| 1-(1-Methyl-4-piperidinyl)piperazine | 23995-88-2 | / | / |
| methyl (2R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate dihydrochloride | 1414976-14-9 | / | / |
| 1H-Indazole-5-propanoic acid,α-amino-7-methyl-,methyl ester, (αR)- | 890044-58-3 | / | / |
| 1-(1-METHYLPIPERIDIN-4-YL)PIPERAZINE 3HCL | 349535-15-5 | / | / |
Other programs under Z
Building toward Zavegepant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →